Recombinant humanized IgG4 anti-SIRPα antibody（Daiichi Sankyo）
N/A
Report date: 2023/03/14 20:00:30
Base Information
Drug NameRecombinant humanized IgG4 anti-SIRPα antibody（Daiichi Sankyo）
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[4]
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A